N@N

Market Maker Surveillance Report. KKD, KKD, RPTP, RPTP, ORS, ORS, Winning Stocks With Lowest Price Friction For Monday, May 23

May 23, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 2514 companies with "abnormal" market making, 1231 companies with positive Friction Factors and 4207 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. KRISPY KREME DOUGHNUTS INC (NYSE:KKD), KRISPY KREME DOUGHNUTS INC (NYSE:KKD), RAPTOR PHARMACEUTICAL CORP (OTCBB:RPTP), RAPTOR PHARMACEUTICAL CORP (OTCBB:RPTP), ORSUS XELENT TECHNOLOGIES IN (AMEX:ORS), ORSUS XELENT TECHNOLOGIES IN (AMEX:ORS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     KKD        $1.610       25.16%       4,588,801       34.14%       4,457,325       33.16%       131,476         817     
     KKD        $1.610       25.16%       4,588,801       34.14%       4,457,325       33.16%       131,476         817     
     RPTP       $0.860       21.55%       1,584,846       62.99%       913,195         36.30%       671,651         7,810   
     RPTP       $0.860       21.55%       1,584,846       62.99%       913,195         36.30%       671,651         7,810   
     ORS        $1.280       117.43%      504,862         31.05%       419,438         25.79%       85,424          667     
     ORS        $1.280       117.43%      504,862         31.05%       419,438         25.79%       85,424          667     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows KKD with a dollar gain Monday of $1.61000 and a Friction Factor of 817 shares. That means that it only took 817 more shares of buying than selling to move KKD higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

KRISPY KREME DOUGHNUTS INC (NYSE:KKD) - Krispy Kreme Doughnuts, Inc. operates as a branded retailer and wholesaler of doughnuts, complementary beverages and treats, and packaged sweets. It engages in owning and franchising Krispy Kreme doughnut stores, which make, sell, and distribute approximately 20 varieties of doughnuts, including various Original Glazed doughnuts, as well as beverages comprising drip coffees, espresso, cappuccino, hot chocolate, coffee-based and non-coffee-based frozen drinks, juices, sodas, milks, water, and packaged and fountain beverages. The company also provides doughnut mixes, supplies, and ingredients to franchisees, as well as manufactures and sells doughnut-making equipment. As of January 30, 2011, it operated 646 Krispy Kreme stores consisting of 85 company owned stores, 144 the United States franchise stores, and 417 international franchise stores. The company offers its products through on-premises sales, which comprise sales to customers visiting its factory and satellite stores, including sales made through drive-through windows along with discounted sales to community organizations; and off-premises sales, which comprise sales to various retail customers, such as convenience stores, grocery stores/mass merchants, and other food service and institutional accounts. Krispy Kreme Doughnuts, Inc. was founded in 1937 and is headquartered in Winston-Salem, North Carolina.

KRISPY KREME DOUGHNUTS INC (NYSE:KKD) - Krispy Kreme Doughnuts, Inc. operates as a branded retailer and wholesaler of doughnuts, complementary beverages and treats, and packaged sweets. It engages in owning and franchising Krispy Kreme doughnut stores, which make, sell, and distribute approximately 20 varieties of doughnuts, including various Original Glazed doughnuts, as well as beverages comprising drip coffees, espresso, cappuccino, hot chocolate, coffee-based and non-coffee-based frozen drinks, juices, sodas, milks, water, and packaged and fountain beverages. The company also provides doughnut mixes, supplies, and ingredients to franchisees, as well as manufactures and sells doughnut-making equipment. As of January 30, 2011, it operated 646 Krispy Kreme stores consisting of 85 company owned stores, 144 the United States franchise stores, and 417 international franchise stores. The company offers its products through on-premises sales, which comprise sales to customers visiting its factory and satellite stores, including sales made through drive-through windows along with discounted sales to community organizations; and off-premises sales, which comprise sales to various retail customers, such as convenience stores, grocery stores/mass merchants, and other food service and institutional accounts. Krispy Kreme Doughnuts, Inc. was founded in 1937 and is headquartered in Winston-Salem, North Carolina.

RAPTOR PHARMACEUTICAL CORP (OTCBB:RPTP) - Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntingtons Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

RAPTOR PHARMACEUTICAL CORP (OTCBB:RPTP) - Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntingtons Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

ORSUS XELENT TECHNOLOGIES IN (AMEX:ORS) - Orsus Xelent Technologies, Inc., together with its subsidiaries, engages in the design, manufacture, and distribution of cellular phones for retail and wholesale distribution in the Peoples Republic of China. It offers cell phones for global system for mobile communications (GSM) and code division multiple access (CDMA) platforms. The company distributes its products through national sales distributors and dealers. It has strategic partnerships with CEC Mobile Co., Ltd., Beijing Xingwang Shidai Tech & Trading Co., Ltd., and CECT-Chinacom Communications Co., Ltd. The company was formerly Universal Flirts Corp. and changed its name to Orsus Xelent Technologies, Inc. in April 2005. Orsus Xelent Technologies, Inc. was founded in 2004 and is headquartered in Beijing, the People's Republic of China.

ORSUS XELENT TECHNOLOGIES IN (AMEX:ORS) - Orsus Xelent Technologies, Inc., together with its subsidiaries, engages in the design, manufacture, and distribution of cellular phones for retail and wholesale distribution in the Peoples Republic of China. It offers cell phones for global system for mobile communications (GSM) and code division multiple access (CDMA) platforms. The company distributes its products through national sales distributors and dealers. It has strategic partnerships with CEC Mobile Co., Ltd., Beijing Xingwang Shidai Tech & Trading Co., Ltd., and CECT-Chinacom Communications Co., Ltd. The company was formerly Universal Flirts Corp. and changed its name to Orsus Xelent Technologies, Inc. in April 2005. Orsus Xelent Technologies, Inc. was founded in 2004 and is headquartered in Beijing, the People's Republic of China.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net